The FDA has confirmed that it will convene an advisory committee meeting on 10th June to discuss Eli Lilly’s Alzheimer’s disease candidate donanemab, after announcing a delay to its review ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback